Repurposing existing drugs for vascular dementia (VaD) could have clinical impact. Here, using Mendelian randomization, researchers tested whether cholesterol, anti-inflammatory or blood pressure drug targets affect risk of VaD, finding little evidence to support repurposing opportunities. A potential benefit was seen for beta-blocker target ADRB1 while ACE inhibition was observed to potentially increase risk of VaD.
- Victoria Taylor-Bateman
- Phazha Bothongo
- Emma L. Anderson
